Boron in drug design: Recent advances in the development of new therapeutic agents.

Show simple item record

dc.contributor.author Fernandes, Guilherme Felipe Santos
dc.contributor.author Denny, William Alexander
dc.contributor.author Dos Santos, Jean Leandro
dc.coverage.spatial France
dc.date.accessioned 2022-02-09T22:11:09Z
dc.date.available 2022-02-09T22:11:09Z
dc.date.issued 2019-10
dc.identifier.citation European journal of medicinal chemistry 179:791-804 Oct 2019
dc.identifier.issn 0223-5234
dc.identifier.uri https://hdl.handle.net/2292/58133
dc.description.abstract Advances in the field of boron chemistry have expanded the application of this element in Medicinal Chemistry. Boron-containing compounds represent a new class for medicinal chemists to use in their drug designs. Bortezomib (Velcade<sup>®</sup>), a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-containing compounds. After its approval, two other boron-containing compounds have been approved, tavaborole (Kerydin<sup>®</sup>) for the treatment of onychomicosis and crisaborole (Eucrisa<sup>®</sup>) for the treatment of mild to moderate atopic dermatitis. A number of boron-containing compounds have been described and evaluated for a plethora of therapeutic applications. The present review is intended to highlight the recent advances related to boron-containing compounds and their therapeutic applications. Here, we focused only in those most biologically active compounds with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years.
dc.format.medium Print-Electronic
dc.language eng
dc.publisher Elsevier BV
dc.relation.ispartofseries European journal of medicinal chemistry
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm
dc.subject Animals
dc.subject Humans
dc.subject Onychomycosis
dc.subject Multiple Myeloma
dc.subject Dermatitis, Atopic
dc.subject Boron Compounds
dc.subject Drug Design
dc.subject Bortezomib
dc.subject Bridged Bicyclo Compounds, Heterocyclic
dc.subject Benzoxaboroles
dc.subject Biological activity
dc.subject Boron
dc.subject Boron-containing compounds
dc.subject Boronic acids
dc.subject Drug design
dc.subject Animals
dc.subject Boron Compounds
dc.subject Bortezomib
dc.subject Bridged Bicyclo Compounds, Heterocyclic
dc.subject Dermatitis, Atopic
dc.subject Drug Design
dc.subject Humans
dc.subject Multiple Myeloma
dc.subject Onychomycosis
dc.subject Science & Technology
dc.subject Life Sciences & Biomedicine
dc.subject Chemistry, Medicinal
dc.subject Pharmacology & Pharmacy
dc.subject Boron
dc.subject Drug design
dc.subject Boron-containing compounds
dc.subject Biological activity
dc.subject Boronic acids
dc.subject Benzoxaboroles
dc.subject CXCR1/2 ANTAGONISTS OPTIMIZATION
dc.subject ACID PROTEASOME INHIBITORS
dc.subject SERINE BETA-LACTAMASES
dc.subject IN-VIVO EVALUATION
dc.subject MYCOBACTERIUM-TUBERCULOSIS
dc.subject BIOLOGICAL EVALUATION
dc.subject DEVELOPMENT CANDIDATE
dc.subject CARBONIC-ANHYDRASES
dc.subject LEAD OPTIMIZATION
dc.subject EFFLUX PUMP
dc.subject 0305 Organic Chemistry
dc.subject 0304 Medicinal and Biomolecular Chemistry
dc.subject 0305 Organic Chemistry
dc.subject 1115 Pharmacology and Pharmaceutical Sciences
dc.title Boron in drug design: Recent advances in the development of new therapeutic agents.
dc.type Journal Article
dc.identifier.doi 10.1016/j.ejmech.2019.06.092
pubs.begin-page 791
pubs.volume 179
dc.date.updated 2022-01-10T00:59:46Z
dc.rights.holder Copyright: 2019 Elsevier Masson SAS. All rights reserved. en
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/31288128
pubs.end-page 804
pubs.publication-status Published
dc.rights.accessrights http://purl.org/eprint/accessRights/RetrictedAccess en
pubs.subtype Review
pubs.subtype Journal Article
pubs.elements-id 776741
dc.identifier.eissn 1768-3254
dc.identifier.pii S0223-5234(19)30619-1


Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics